Ariel Appreciation Fund reported a -3.90% return in Q3 2026, underperforming the Russell Midcap Value and Midcap Indexes. The fund made key portfolio changes including selling NCLH shares to buy Royal Caribbean Group, acquiring ADI Global Distribution after its spin-off, and Middleby’s spin-off of Midera Food Processing alongside share buybacks. Charles River Laboratories showed strong earnings and raised its full-year guidance, contributing positively. These moves reflect Ariel's active management approach amid a challenging market environment.
As of Oct 28, 2026 14:01 WIB, Charles River Laboratories (CRL) trades at its 52-week high of USD 358.84, up 0.44% on the day, contrasting with Norwegian Cruise Line Holdings (NCLH) near its 52-week low at USD 15.70, down 0.32%. Meanwhile, Royal Caribbean Cruises (RCL) stands closer to its 52-week high at USD 295.71 but is slightly down 0.07%, reflecting varied investor sentiment on these cruise and health sector stocks on Pluang.
